Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia?

Journal of Psychiatric Research

Volumn 32, Issue 3-4, 1998, Pages 229-242

  DeQuardo, John R ^a   Tandon, Rajiv ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

COGNITIVE DEFECT; DETERIORATION; DISEASE COURSE; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE COST; HUMAN; NEUROBIOLOGY; PRIORITY JOURNAL; PSYCHOSOCIAL DISORDER; REVIEW; SCHIZOPHRENIA; SYMPTOMATOLOGY; TARDIVE DYSKINESIA;

ANTIPSYCHOTIC AGENTS; BRAIN; COGNITION DISORDERS; DISEASE PROGRESSION; HUMANS; SCHIZOPHRENIA; TIME FACTORS;

EID: 0032073457     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3956(98)00024-7     Document Type: Review

References (111)

1. Addington DE, Jones B, Bloom D, Choiunard G, Remington G, Albright P. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993;15:917-926.
2. Aitchison KJ, Kerwin RW. Cost-effectiveness of clozapine. Br J Psychiatry 1997;171:125-130.
3. Albright PS, Livingstone S, Keegan D, et al. Reduction of healthcare resource utilization and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy; a retrospective analysis using the Saskatchewan Health linkable databases. Clin Drug Invest 1996;11:289-299.
4. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997;154 (Suppl.):1-63.
5. Ansis GM, Kaplan ML, Hundorfean G, Saeed W. Violence and homicidal behaviors in psychiatric disorders. Psychiatric Clin North Am 1997;20:405-425.
6. The Seroquel Trial 13 Study Group, Arvanitis LA, Miller BG. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-246.
7. Avnon M, Rabinowitz J. Effectiveness of clozapine in hospitalized people with chronic neuroleptic-resistant schizophrenia. Br J Psychiatry 1995;167:760-764.
8. Beasley CM, Sayler ME, Kiesler GM, Potvin JH, Sanger TM, Tollefson GD. The influence of pharmacotherapy on self-directed and externally-directed aggression in schizophrenia. Schizophrenia Res 1998;29:28.
9. Bilder RM, Lipschutz-Broch L, Reiter G, Geisler SH, Mayerhoff DI, Lieberman JA. Intellectual deficits in first-episode schizophrenia: evidence for progressive deterioration. Schizophrenia Bull 1992;18:437-448.
10. Bilder RM. Neurocognitive impairment in schizophrenia and how it affects treatment options. Can J Psychiatry 1997;42:255-264.
11. Borison RL. The role of cognition in the risk-benefit and safety analysis of antipsychotic medication. Acta Psychiatrica Scand 1996;94:5-11.
12. Brecher M. Long-term safety of risperidone. Eur Neuropsychopharmacol 1996;6 (Suppl. 3):170.
13. Breier A, Buchanan RW, Irish D, Carpenter WT Jr. Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hospital Community Psychiatry 1993;44:1145-1149.
14. Buckley P, Bartell J, Donewirth K, Lee S, Torioe F, Schultz SC. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law 1995;23:607-611.
15. Buckley PF, Ibrahim ZY, Singer B, Orr B, Donenwirth K, Brar PS. Aggression and schizophrenia: efficacy of risperidone. J Am Acad Psychiatry Law 1997;25:173-181.
16. Buckley PF. Treatment of schizophrenia: let's talk dollars and sense. Am J Managed Care 1998;4:369-383.
17. Caldwell CB, Gottesman II. Schizophrenia: a high risk factor for suicide. Clues to risk reduction. Suicide Life Threat Behav 1992;22:479-493.
18. Canadian Cognition and Outcome Study Group. Neuropsychological change in early phase schizophrenia over twelve months of treatment with olanzapine, risperidone, or haloperidol. Schizophrenia Res 1998;29:152-153.
19. Carpenter WT, Hanlon, Thomas TE, Heinrichs DW, Summerfeit AT, Kirkpatrick B, Levine J, Buchanan RW. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 1990;147:1138-1148.
20. Casey DE. Motor and mental aspects of EPS. Int Clin Psychopharmacol 1995;10:105-114.
21. Chakos MH, Lieberman JA, Bilder RM, Lerner G, Bogerts B, Degreef G, Wu H, Ashtari M. Increase in caudate volumes of first episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry 1994;151:1430-1436.
22. Chakos MH, Lieberman JA, Alvir J, Bilder RM, Ashtari M. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet 1995;345:456-457.
23. Chouinard G, Annable L, Mercier P, Ross-Chouinard A. A five-year follow-up study of tardive dyskinesia. Psychopharmacol Bull 1986;22:259-263.
24. Csernansky JG, Newcomer JG. Maintenance drug treatment for schizophrenia. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1995. p. 1267-75.
25. Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry 1994;165:18-21.
26. Davis JM. Overview: maintenance therapy in psychiatry: I. Schizophrenia. Am J Psychiatry 1975;132:1237-1245.
27. Davis JM. Maintenance therapy and the natural course of schizophrenia. J Clin Psychiatry 1985;46:18-21.
28. Delay J, Deniker P, Harl JM. Utilisation en therapeutique psychiatrique d'une phenothiazine d'action centrale elective. Ann Med-Psychol 1952;110:112-117.
29. DeLisi LE, Sakuma M, Tew W, Kushner M, Hoff AL, Grimson R. Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res Neuroimaging 1997;74:129-140.
30. Dellva MA, Tran PV, Tollefson GD, Wentley AL, Beasley CM. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatric Services 1997;48:1571-1577.
31. DeQuardo JR, Tandon R, Goldman R, Meador-Woodruff JH, Giroux M, Brunberg JA, Kim L. Ventricular enlargement, neuropsychological status, and premorbid function in schizophrenia. Biol Psychiatry 1994;35:517-524.
32. DeQuardo JR. Pharmacologic treatment of first-episode schizophrenia: early intervention is key to outcome. J Clin Psychiatry 1998 (in press).
33. Dixon LB, Leliman AR, Levine J. Conventional antipsychotic medications for schizophrenia. Schizophrenia Bull 1995;21:567-577.
34. Flannery RB, Hanson A, Penk W. Patients' threats: expanded definitions of assault. Gen Hospital Psychiatry 1995;17:451-453.
35. Franz M, Lis S, Pluddemann K, Gallhofer B. Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br J Psychiatry 1997;170:422-425.
36. Frazier JA, Giedd JN, Kaysen D, Albus K, Hamberger S, Alaghband-Rad J, Lenane MC, McKenna K, Brier A, Rapoport JL. Childhoodonset schizophrenia: brain MRI rescan after 2 years of clozapine maintenance treatment. Am J Psychiatry 1996;153:564-566.
37. Fulton B, Goa KL. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 1997;53:281-298.
38. Gaebel W, Pietzcker A. Multidemensional study of the outcome of schizophrenic patients 1 year after clinic discharge. Eur Arch Psychiatry Neurol Sci 1985;235:45-52.
39. Gallhofer B, Bauer U, Lis S, Krieger S, Gruppe H. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 1996;6 (Suppl. 2):13-20.
40. Gerlach J. Oral versus depot administration of neuroleptics in relapse prevention. Acta Psychiatrica Scand 1994;89 (Suppl. 382):28-32.
41. Gilbert PL, Harris MJ, McAdams LA, Jeste DJ. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry 1995;52:173-188.
42. Glazer WM, Dickson RA. Clozapine reduces violence and persistent aggression in schizophrenia. J Clin Psychiatry 1998;59 (Suppl. 3):8-14.
43. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, Schultz SC, Weinberger DR. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 1993; 162:43-48.
44. Goldman RS, Tandon R, Liberzon I, Greden JF. Measurement of depression and negative symptoms in schizophrenia. Psychopathology 1992;25:49-56.
45. Greden JF, Tandon R. Long-term treatment for lifetime disorders?. Arch Gen Psychiatry 1995;52:197-200.
46. Green MF, Marshall BD, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J. Does risperidone improve verbal working memory in treatment-resistant schizophrenia?. Am J Psychiatry 1997;154:799-804.
47. Gutierrez-Esteinou R, Grebb JA. Risperidone: an analysis of the first three years in general use. Int Clin Psychopharmacol 1997;12 (Suppl. 4):S3-S10.
48. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic receiving clozapine. Biol Psychiatry 1993;34:702-712.
49. Hamilton SH, Genduso LA, Revecki DA. Medical resource use and work and social outcomes for olanzapine compared with haloperidol in the treatment of schizophrenia and other psychotic disorders. Schizophrenia Res 1998a;29:148-149.
50. Hamilton SH, Revicki DA, Genduso LA, Beasley CM. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 1998b;18:41-49.
51. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994;151:1409-1416.
52. Heinrichs DW, Hanlon TE, Carpenter WT. The quality-of-life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bull 1984;10:388-398.
53. Hellewell JSE, Cameron-Hands D, Cantillon M. Seroquel: evidence for efficacy in the treatment of hostility and aggression. Schizophrenia Res 1998;29:154-155.
54. Hirsch SR, Jolley AG. The dysphoric syndrome in schizophrenia and its implications for relapse. Br J Psychiatry 1989;155 (Suppl. 5):46-50.
55. Hyde TM, Nawroz S, Goldberg TE, Bigelow LB, Strong D, Ostrem JL, Weinberger DR, Kleinman JE. Is there cognitive decline in schizophrenia? A crosssectional study. Br J Psychiatry 1994;164:494-500.
56. Janicak PG, Davis JM, Preskorn SH, Ayd FJ. Principles and practice of psychopharmacology. Baltimore: Williams and Wilkins, 1997. p. 188-217.
57. Jibson MD, Tandon R. The negative symptoms of schizophrenia. Directions in Psychiatry 1995;15:1-7.
58. Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatric Res 1998 (in press).
59. Kane JM, Rifkin A, Woerner MG, Reardon GT, Sarantakos S, Schiebel D, Ramos-Lorenzi J. Arch Gen Psychiatry 1983;40:893-896.
60. Clozaril Collaborative Study Group, Kane J, Honigfeld G, Singer J, Meltzer HY. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.
61. Kane JM, Marder SR. Psychopharmacological treatment of schizophrenia. Schizophrenia Bull 1993;19:287-302.
62. Kay SR, Fizbein A, Opler LA. The positive and negative syndrome scale. Schizophrenia Bull 1987;13:261-276.
63. Keshavan MS, Bagwell WW, Haas GL, Sweency JA, Schooler NR, Pettegrew JW. Changes in caudate volume with neuroleptic treatment. Lancet 1994;344:1434.
64. Kissling W. Ideal and reality of neuroleptic relapse prevention. Br J Psychiatry 1992;161 (Suppl. 18):133-139.
65. Lee MA, Thompson P, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 1994;55 (Suppl. B):82-87.
66. Lieberman J, Johns C, Cooper T, Pollack S, Kane JM. Clozapine pharmacology and tardive dyskinesia. Psychopharmacology (Berlin) 1989;99 (Suppl.):S54-S59.
67. Lindstrom LH. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatrica Scand 1988;77:525-529.
68. Lindstrom E, Ericksson B, Hellgren A, Von Knorring L, Eberhard G. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995;17:402-412.
69. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835.
70. May PRA, Tuma AH, Dixon WJ. Schizophrenia: a follow-up study of results of treatment II. Hospital stay over two to five years. Arch Gen Psychiatry 1976;33:481-486.
71. May PRA, Turna AH, Dixon WJ, Yale C, Theile DA, Kraude WH. Schizophrenia: a follow-up study of the results of five forms of treatment. Arch Gen Psychiatry 1981;38:776-784.
72. McEvoy JP. A double-blind crossover comparison of antiparkinsonian drug therapy: amantadine versus anticholinergies in 90 normal volunteers, with an emphasis on differential effects on memory function. J Clin Psychiatry 1987;48 (Suppl. 9):20-23.
73. McGlashan TH, Fenton WS. The positive-negative distinction in schizophrenia: review of natural history validators. Arch Gen Psychiatry 1992;49:63-72.
74. McGurk SR, Meltzer HY. The effects of atypical antipsychotic drugs on cognitive functioning in schizophrenia. Schizophrenia Res 1998;29:160.
75. Meltzer HY. Dimensions of outcome with clozapine. Br J Psychiatry 1992;160 (Suppl. 17):46-53.
76. Meltzer HY. Suicide in schizophrenia: risk factors and clozapine treatment. J Clin Psychiatry 1998;59 (Suppl. 3): 15-20.
77. Meltzer HY, Fatemi H. Suicide in schizophrenia: the effect of clozapine. Clin Neuropharmacol 1995;18 (Suppl. 3):S18-S24.
78. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit analysis. Am J Psychiatry 1995;152:183-190.
79. Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, Snitz B. Cost effectiveness of clozapine in neuroleptic resistant schizophrenia. Am J Psychiatry 1993;150:1630-1638.
80. Meltzer HY, Thompson PA, Lee MA, Ranjan R. Neuropsychologic deficits in schizophrenia. Relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology 1996;14:27S-33S.
81. Meltzer HY, Casey DE, Garver DL, Lasagna L, Marder SR, Masand P, Miller D, Pickar D, Tandon R. Assessing the negative symptom data on atypical antipsychotics. J Clin Psychiatry 1998;59 (Suppl.) (in press).
82. Moller HJ, Muller H, Borison RL, Schooler NR, Chouinard G. A pathanalytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: a reevaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 1995;245:45-49.
83. Reid WH, Mason M, Toprac M. Savings in hospital bed days related to treatment with clozapine. Hospital Community Psychiatry 1994;45:261-264.
84. Remington G. Understanding schizophrenia: the impact of novel antipsychotics. Can J Psychiatry 1995;40 (Suppl. 2):S29-S32.
85. Reviaki DA, Murray M. Assessing health related quality of life outcomes of drug treatments for psychiatric disorders. CNS Drugs 1994;1:465-476.
86. Revicki DA, Luce BR, Wechsler JM, et al. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hospital Community Psychiatry 1990;41:850-854.
87. Rice DP, Miller LS. The economic burden of schizophrenia: conceptual and methodological issues and cost estimates. In: Moscarelli M, Rupp A, Sartorius N, editors. Schizophrenia, vol. 1: Handbook of Mental Health Economics and Health Policy. London: John Wiley and Sons, 1996. p. 321-34.
88. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997;337:809-815.
89. Saykin AJ, Schtasel DL, Gur RE, Kester BD, Mozley LH, Stafiniak P, Gur RC. Neuropsychological deficits in neuroleptic naive patients with firstepisode schizophrenia. Arch Gen Psychiatry 1994;51:124-131.
90. Schooler NR. Reducing dosage in maintenance treatment of schizophrenia. Br J Psychiatry 1993;163 (Suppl. 22):58-65.
91. Siris SG. Diagnosis of secondary depression in schizophrenia: implications for DSM IV. Schizophrenia Bull 1991;17:75-98.
92. Siris SG. Depression and schizophrenia. In: Hirsch SR, Weinberger DR, editors. Schizophrenia. Oxford: Blackwell Science, 1995. p. 128-45.
93. Siris SG, Morgan V, Fagerstrom R, Rifkin A, Cooper TB. Adjunctive imipramine in the treatment of postpsychotic depression: a controlled trial. Arch Gen Psychiatry 1987;44:533-539.
94. Siris SG, Bermanzohn PC, Mason SE, Shuwall MA. Maintenance imipramine therapy for secondary depression in schizophrenia: a controlled trial. Arch Gen Psychiatry 1994;51:109-115.
95. Small JG, Milstein V, Marhenke JD, Hall DO, Kellams JJ. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatmentresistant psychosis. J Clin Psychiatry 1987;48:263-267.
96. The Seroquel Study Group, Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG. Quetiapine in patients with schizophrenia. A high-and low-dose doubleblind comparison with placebo. Arch Gen Psychiatry 1997;54:549-557.
97. Strauss JS, Carpenter WT. The prediction of outcome in schizophrenia. Arch Gen Psychiatry 1972;27:739-746.
98. Tandon R, Goldman R, DeQuardo JR, Goldman M, Perez M, Jibson MD. Positive and negative symptoms covary during clozapine treatment in schizophrenia. J Psychiatric Res 1993;27:341-347.
99. Tandon R, Jibson MD, Taylor SF, DeQuardo JR. Conceptual models of the relationship between positive and negative symptoms. In: Shriqui CL, Nasrallah HA, editors. Contemporary Issues in the Treatment of Schizophrenia. Washington D.C.: American Psychiatric Press, 1995. p. 109-24.
100. Tandon R. Cholinergic aspects of schizophrenia. Br J Psychiatry 1998a (in press).
101. Tandon R. Antipsychotic agents. In: Current Psychotherapeutic Drugs. New York: Brunner/Mazel Publishers, 1998b. p. 120-54.
102. Tollefson GD. Economics of schizophrenia. Scientific Proceedings, 150th Annual Meeting of the American Psychiatric Association. San Diego, 1997.
103. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997;154:466-74.
104. Tollefson GD, Beasley CM, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997a;154:1248-1254.
105. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME. Olanzapine versus haloperidol in the treatment of schizophrenia and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997b; 154:457-465.
106. Tollefson GD, Sanger TM, Lu Y, Thieme ME. Depressive signs and symptoms in schizophrenia. A prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1997c;55:250-258.
107. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley CM, Tollefson GD. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418.
108. Wirshing WC, Ames D, Marder SR, Marshall BD, Green MF, MeGurk S. Risperidone in treatment resistant schizophrenia: preliminary results. Schizophrenia Res 1996;18:130.
109. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophrenia Bull 1991;17:325-351.
110. Wyatt RJ, Green MF, Turna AH. Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: a reanalysis of the Camarillo State Hospital data. Psychol Med 1997;27:261-268.
111. Zubin J, Steinhauer SR, Condray R. Vulnerability to relapse in schizophrenia. Br J Psychiatry 1992;161 (Suppl. 18):13-18.